Roche's MabThera gets green light in Scotland; J&J sues BI unit over arbitration disagreement; China's diabetes problem continues to grow;

@FiercePharma: GSK unloading drinks brands to Japan's Suntory for $2.1B. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: New FDA guidance on generics for combo inhaled drugs is bad news for GSK/Advair. Article | Follow @CarlyHFierce

> Cost regulators have given the green light to Roche's ($RHHBY) MabThera (also known as Rituxan) and Otsuka's Abilify, among others, for use in Scotland's National Health Service. Report

> Johnson & Johnson ($JNJ) sued a unit of Boehringer Ingelheim over whether a dispute over an agreement must be heard by an arbitrator. Item

> South African's government has drafted drug patent reforms that, if accepted, could increase competition and lower the cost of medicines in the country. Story

> KKR is likely to buy stake in Hyderabad-based Gland Pharma, a report says. Item

> The medical school at Canada's Western University and a major hospital in London, Ontario, Canada, have launched a probe into allegations that a pharma company exerted "undue influence" on the school's ophthalmology department. Story

> Italy's Recordati has agreed to acquire Spanish pharma company Laboratorios Casen Fleet S.L.U. for €93 million ($123 million). Item

Medical Device News

@FierceMedDev: Intuitive's surgical robots slammed in another study. Story | Follow @FierceMedDev

@DamianFierce: Another FDA roadblock for Guided Therapeutics and its cervical scanner. Article | Follow @DamianFierce

@MarkHFierce: NanoString is ramping up the U.S. commercial launch for its breast cancer prognostic Dx. Item | Follow @MarkHFierce

@MichaelGFierce: CeQur closes $27M round to fund insulin delivery device. More from FierceDrugDelivery | Follow @MichaelGFierce

> Why was J&J's latest metal hip liability trial delayed two weeks? Story

> Consumer group demands warranties for hip, knee implants. More

Biotech News

@FierceBiotech: Merck R&D chief spotlights streamlining, biologics and the new risk strategy. Article | Follow @FierceBiotech

@JohnCFierce: You can add real estate to AstraZeneca's (long) list of bad investments. Story | Follow @JohnCFierce

@Ry_McBride: Busy Biogen Idec fuels Amicus in Parkinson's drug chase. More | Follow @Ry_McBride

> Remicade knockoff delivers pioneering antibody biosimilar OK for Hospira, Celltrion. Story

> Roche's cancer immunotherapy quest spurs $422.5M Inovio combo deal. Article

> Neurocrine shares damaged by low-dose drug pratfall in PhIIb. Story

> Cold Spring Harbor Lab names Teri Willey as new BD chief. Item

Biotech Research News

@EmilyMFierce: Drug combo could treat deadly coronavirus. More | Follow @EmilyMFierce

> Immune cell discovery could help fight diabetes, arthritis, MS. Story

> Amicus, Biogen Idec form Parkinson's drug development pact. News

> Potential Parkinson's-fighting compounds identified. Article

> Compound restores learning deficits in Down syndrome mice. More

> Advaxis treatment stops HPV tumor growth, extends survival in animals. Item

Pharma Manufacturing News

@EricPFierce: J&J recalls infant Motrin after API found to have tiny plastic bubbles. Story | Follow @EricPFierce

> India's economic meltdown pushes Biocon to build elsewhere. Story

> Piramal investing $11M in U.K. plant. News

> Burglar admits heists at Lilly, Glaxo warehouses. Report

> Altaire recalls moldy eye solution made for Walmart, CVS, Target. More

> Banner manufacturing powers Patheon growth. Article

And Finally... China's diabetes epidemic is now the biggest in the world, with 11.6% of Chinese adults affected, a new study says. Report (sub. req.)

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

The countdown to the FDA's first coronavirus vaccine hearing has begun, and new agency documents outline an agenda for the Thursday confab.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.